IRQ Articles

JVIR Editor's awards recognize outstanding research 

25 days ago

SIR Today 2021 banner

SIR Today 2021| April 13, 2021

On Friday, March 26, Ziv J Haskal, MD, FSIR, emeritus editor-in-chief of Journal of Interventional Radiology (JVIR), presented the JVIR Editor's Awards for 2020 and 2019, for outstanding clinical and laboratory research. He then presented the awards for top JVIR reviewers of 2019 and 2020. After the awards, incoming JVIR Editor-in-chief Daniel Y. Sze, MD, PhD, FSIR, discussed the strengths of the journal and his vision for its continued growth in the years ahead. 

SIR Today asked the paper award recipients to share more details on their research and the anticipated impact of their findings. 

See the full list of award recipients. View the award presentation. 

 

2020 JVIR Editor’s Awards

Scott O. Trerotola, MD, Outstanding Clinical Research

Trerotola SO, Saad TF, Roy-Chaudhury P, Lutonix AV Clinical Trial Investigators. The Lutonix AV randomized trial of Paclitaxel-coated balloons in arteriovenous fistula stenosis: 2-year results and subgroup analysis. J Vasc Interv Radiol. 2020 Jan;31(1):1-14.e5.

Our paper was the final report of a randomized trial on paclitaxel-coated balloons. The study was the first of its kind and set the standard for how to approach this type of trial. It ended up being a negative study—we didn’t meet the endpoint of proving that drug-coated balloons are more efficacious, but it did show some benefits for patients.

This area of research is important because it’s so patient-focused. Individuals undergoing dialysis are often miserable, because they spend their life getting treatments or waiting for treatments. The less time they have to spend on dialysis, the better their lives are. There are ways to give them more options, and while it was disappointing that we had a negative result, we’re encouraged by the possibilities.

 

Haruyuki Takaki, MD, Outstanding Laboratory Investigation

Takaki H, Hirata Y, Ueshima E, Kodama H, Matsumoto S, Wada R, Suzuki H, Nakasho K, Yamakado K. Hepatic artery embolization enhances expression of programmed cell death 1 ligand 1 in an orthotopic rat hepatocellular carcinoma model: In vivo and in vitro experimentation. J Vasc Interv Radiol. 2020 Sep;31(9):1475-1482.e2.

In this study, we evaluated the effects of hepatic artery embolization (HAE) on the expression of programmed cell death 1 ligand 1 (PD-L1), which is one of the most important molecules that promote cancer immune evasion. Because PD-L1 promotes the cancer immune evasion, overexpression of PD-L1 is known as a negative prognostic factor in patients with HCC and many other malignancies. Results of our study showed that HAE has some potential to reduce the antitumor immune response by enhancing the expression of PD-L1 and by promoting immune evasion in cancer.

In addition to showing the potential of HAE, our study also showed that the overexpression of PD-L1 was triggered by HIF-1 dependent manner. Therefore, if we can neutralize the PD-L1 or suppress the HIF-1 expression at the time of HAE, we may enhance the effect of HAE. The finding of our study may lead to the development of more effective HAE.

 

2019 JVIR Editor’s Awards

Belinda A. Mohr, PhD—Outstanding Clinical Research

Mohr BA, Sheen AL, Roy-Chaudhury P, Schultz SR, Aruny JE; REVISE Investigators. Clinical and economic benefits of stent grafts in dysfunctional and thrombosed hemodialysis access graft circuits in the REVISE randomized trial. J Vasc Interv Radiol. 2019, 30: 203-211.e4

Our research examined the number of repeat procedures and associated costs to maintain a dialysis access circuit after treating the underlying lesion with standard percutaneous transluminal angioplasty (PTA) alone or with a stent graft. We showed that the use of a stent graft significantly reduced the number of repeat interventions for all patients and significantly reduced the number of costs for those that presented with a thrombosed circuit over a 24-month period.

I anticipate that this research would have a positive impact on dialysis access patients since it informs physicians of the most cost-effective treatment options available that positively impact patient outcomes.

This research is important because it demonstrates which treatments improve the lives of dialysis access patients. Patients can continue to have uninterrupted dialysis sessions without the burden and stress of needing procedure after procedure to keep the graft open. Understanding the costs of these treatments and whether they add value to the healthcare system is also very important given the increasing costs of health care.

 

Yuchen Huo, MA—Outstanding Laboratory Investigation

Huo Y, Chen WS, Lee J, Feng GS, Newton IG. Stress conditions induced by locoregional therapies stimulate enrichment and proliferation of liver cancer stem cells. J Vasc Interv Radiol. 2019, 30: 2016-2025.e5.

This study tested the hypothesis that stress conditions that simulated percutaneous thermal ablation (PTA), transarterial embolization (TAE) or transarterial chemoembolization stimulated enrichment of hepatocellular carcinoma (HCC) cancer stem cells (hCSCs) and that hCSC inhibitors can suppress this effect.

Connect with SIR

AD: Cook Medical

ADVERTISEMENT